<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03730441</url>
  </required_header>
  <id_info>
    <org_study_id>ADR</org_study_id>
    <nct_id>NCT03730441</nct_id>
  </id_info>
  <brief_title>Correlation Between ADR of Screening and All Colonoscopies</brief_title>
  <official_title>Correlation Between ADR of Screening and All Colonoscopies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Frydek-Mistek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Frydek-Mistek</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare ADR for colonoscopies from various indications and to find
      correlations between ADR of screening and all examinations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ADR (adenoma detection rate) is generally accepted quality indicator and it is calculated
      from screening colonoscopies in patients over 50 years of age. For possible gaming with ADR
      for screening colonoscopies, monitoring of ADR for all colonoscopies is discussed
      nowadays.The aim of the study is to compare ADR for colonoscopies from various indications
      and to find correlations between ADR of screening and all examinations.

      We want to retrospectively assess the quality indicators of all colonoscopies performed from
      January 2013 to December 2017. We want to calculate ADR for all colonoscopies in patients
      over 50 years of age excluding therapeutic, IBD, management of complications and
      sigmoidoscopies (screening, surveillance, diagnostic) and separately only for screening
      colonoscopies. Correlation analysis will be performed using Pearson´s correlation
      coefficient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>correlation between ADR of screening and all colonoscopies (screening, surveillance, diagnostic)</measure>
    <time_frame>january 2013 - december 2017</time_frame>
    <description>Pearson´s correlation coefficient</description>
  </primary_outcome>
  <enrollment type="Actual">6925</enrollment>
  <condition>Colon Neoplasm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Colonoscopy</intervention_name>
    <description>Endoscopic examination of large bowel</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        people over 50 years of age coming for colonoscopic examination
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  people over 50 years of age coming for colonoscopic examination (screening,
             surveillance, diagnostic)

        Exclusion Criteria:

          -  age under 50 years

          -  indication for colonoscopy: therapeutic, IBD, management of complications and
             sigmoidoscopies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivana Mikoviny Kajzrlikova</last_name>
    <role>Principal Investigator</role>
    <affiliation>Doctor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Frydek-Mistek</name>
      <address>
        <city>Frýdek-Místek</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 2, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>November 2, 2018</last_update_submitted>
  <last_update_submitted_qc>November 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Frydek-Mistek</investigator_affiliation>
    <investigator_full_name>Ivana Mikoviny Kajzrlikova, MD, PhD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>ADRs of all endoscopists in our unit for both all and screening colonoscopies</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

